Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Ambrx Biopharma Inc ADR (AMAM)
Ambrx Biopharma Inc ADR (AMAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,764,411
  • Shares Outstanding, K 63,150
  • Annual Sales, $ 7,400 K
  • Annual Income, $ -78,000 K
  • 60-Month Beta -1.88
  • Price/Sales 1,925.86
  • Price/Cash Flow N/A
  • Price/Book 6.16
Trade AMAM with:

Options Overview Details

View History
  • Implied Volatility 22.76% ( -4.84%)
  • Historical Volatility 4.86%
  • IV Percentile 1%
  • IV Rank 1.14%
  • IV High 287.11% on 09/22/23
  • IV Low 19.70% on 02/05/24
  • Put/Call Vol Ratio 2.86
  • Today's Volume 27
  • Volume Avg (30-Day) 440
  • Put/Call OI Ratio 1.27
  • Today's Open Interest 37,685
  • Open Int (30-Day) 39,889

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.41
  • Number of Estimates 2
  • High Estimate -0.36
  • Low Estimate -0.45
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.51 +1.62%
on 02/20/24
28.03 -0.27%
on 02/26/24
+0.19 (+0.70%)
since 01/26/24
3-Month
9.25 +202.22%
on 11/27/23
28.15 -0.69%
on 01/10/24
+18.18 (+186.13%)
since 11/24/23
52-Week
4.69 +496.06%
on 02/27/23
28.15 -0.69%
on 01/10/24
+22.92 (+455.77%)
since 02/24/23

Most Recent Stories

More News
3 Pharma Stock Buys With Accelerating Gains

The pharmaceutical industry is expected to thrive as demand increases and technology advances. Therefore, fundamentally strong pharma stocks Neurocrine Biosciences (NBIX), AstraZeneca (AZN) and Johnson...

AMAM : 27.95 (+0.04%)
AZN : 65.88 (+0.08%)
JNJ : 161.00 (-0.52%)
NBIX : 134.07 (-0.08%)
Top 4 Pharma Stocks on the Rise for Potential Gains

Growing medical needs, surging demand for precision medicine, favorable regulatory climate, and rapid digital transformation would create promising growth opportunities for pharma companies. Hence, it...

AMAM : 27.95 (+0.04%)
GNFT : 3.65 (-0.27%)
IPSEY : 28.5475 (+0.28%)
JNJ : 161.00 (-0.52%)
PROC : 3.22 (-2.35%)
SPRO : 1.5450 (+2.32%)
Better Growth Stock: UnitedHealth Group vs. Johnson & Johnson

These companies have been focusing on growing their operations, but which stock is likely to provide investors with better returns?

KVUE : 18.99 (-0.99%)
AMAM : 27.95 (+0.04%)
UNH : 529.09 (+0.35%)
JNJ : 161.00 (-0.52%)
Johnson & Johnson (JNJ): Analyzing Signals Before Quarterly Earnings

Pharmaceutical powerhouse Johnson & Johnson (JNJ) is proactively driving innovation throughout the healthcare spectrum, thanks to its strong focus on innovative medicines and MedTech solutions. However,...

AMAM : 27.95 (+0.04%)
JNJ : 161.00 (-0.52%)
NVO : 123.04 (-0.33%)
NVS : 103.87 (-0.03%)
SNPHY : 10.2650 (+4.00%)
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END

ONCY : 0.9900 (+0.31%)
ONC.TO : 1.34 (-0.74%)
AMGN : 286.46 (-0.94%)
AMAM : 27.95 (+0.04%)
ELEV : 2.59 (+1.25%)
NKTX : 9.91 (+3.23%)
Johnson & Johnson: Biotech a shot in the arm for future growth?

Johnson & Johnson is actively shifting its strategy towards biotechnology and antibody-drug conjugates, balancing current revenue protection with future growth.

JNJ : 161.00 (-0.52%)
AMAM : 27.95 (+0.04%)
Markets Today: Stocks Edge Higher on Hopes Israeli-Hamas Conflict Can Be Contained

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are up +0.38%, and the Dec Nasdaq 100 E-Mini futures (NQZ2 3) are up +0.22%. Stock index futures this morning are moderately higher as the markets...

ESH24 : 5,098.75 (-0.05%)
NQH24 : 18,014.00 (+0.13%)
LULU : 469.23 (+2.48%)
HUBB : 368.40 (+0.71%)
VFS : 5.12 (+1.19%)
ALSN : 74.56 (-0.09%)
DXCM : 117.50 (+1.07%)
CL : 86.54 (+0.34%)
CART : 30.85 (+0.85%)
AMAM : 27.95 (+0.04%)
AAPL : 181.41 (-0.61%)
PFE : 27.20 (-2.02%)
Why Shares of Ambrx Biopharma Soared This Week

A big buy by an asset manager spurred interest in the biotech stock.

AMAM : 27.95 (+0.04%)
Why Shares of Ambrx Biopharma Jumped This Week

The company reported data on its clinical programs at two conferences this week.

RY : 98.18 (-0.49%)
RY.TO : 133.11 (-0.08%)
AMAM : 27.95 (+0.04%)
Ambrx Raises $78 Million and Completes its ATM Program

Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), today announced that it has completed net sales of approximately $78 million of American Depositary Shares (“ADSs”) pursuant to the Company’s at-the-market...

AMAM : 27.95 (+0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 27.98
2nd Resistance Point 27.96
1st Resistance Point 27.95
Last Price 27.95
1st Support Level 27.92
2nd Support Level 27.90
3rd Support Level 27.89

See More

52-Week High 28.15
Last Price 27.95
Fibonacci 61.8% 19.19
Fibonacci 50% 16.42
Fibonacci 38.2% 13.65
52-Week Low 4.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar